Stoke Therapeutics, Inc. announced a private placement of 49,540,132 series A preferred shares at a price of $0.2392 per share and 75,777,370 series A-2 preferred shares at a price of $0.3827 per share for the gross proceeds of $40,849,999.0734 on January 4, 2018. The preferred shares are convertible. The preferred shares are convertible into common shares at their respective original issue price. The preferred shares are entitled to receive non-cumulative dividend of 8% per annum. The transaction was raised at post money valuation of $50,509,984. On same day, the company has received $40,000,000 in its first tranche of series A round of funding from existing investor Apple Tree Partners.